James F. Oliviero III Sells 9,233 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 9,233 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $3.41, for a total transaction of $31,484.53. Following the sale, the chief executive officer now owns 3,785,350 shares in the company, valued at $12,908,043.50. This trade represents a 0.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Checkpoint Therapeutics Stock Up 7.0 %

Shares of Checkpoint Therapeutics stock opened at $3.35 on Thursday. Checkpoint Therapeutics, Inc. has a 52-week low of $1.38 and a 52-week high of $4.50. The company has a market capitalization of $163.58 million, a P/E ratio of -1.82 and a beta of 1.36. The company has a 50 day moving average of $3.38 and a 200 day moving average of $3.00.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). As a group, research analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Checkpoint Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CKPT. Geode Capital Management LLC boosted its position in shares of Checkpoint Therapeutics by 41.2% during the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after acquiring an additional 124,787 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Checkpoint Therapeutics by 160.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after buying an additional 80,000 shares in the last quarter. HB Wealth Management LLC grew its holdings in shares of Checkpoint Therapeutics by 96.9% during the fourth quarter. HB Wealth Management LLC now owns 153,560 shares of the company’s stock worth $513,000 after purchasing an additional 75,560 shares during the last quarter. Walleye Capital LLC purchased a new position in Checkpoint Therapeutics during the 3rd quarter worth approximately $148,000. Finally, Gladstone Institutional Advisory LLC grew its position in shares of Checkpoint Therapeutics by 75.4% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 61,399 shares of the company’s stock worth $196,000 after acquiring an additional 26,399 shares during the last quarter. 22.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CKPT has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. D. Boral Capital began coverage on Checkpoint Therapeutics in a research report on Monday, January 13th. They set a “buy” rating and a $9.00 price objective on the stock. Finally, Lake Street Capital lifted their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a report on Monday, December 16th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.